Benzodiazepines and anxiety disorders: a review for the practicing physician

References

• Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eschleman S, et al. Lifetime and 12-month prevalence of DSMIII-R psychiatric disorders in the United States: results from the national comorbidity survey. Arch Gen Psychiatry 1994;51:8–19
   PubMed Web of Science ®Google Scholar
• Greist JH, Bandelow B, Hollander E, Marazziti D, Montgomery SA, Nutt DJ, et al. WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adults. CNS Spectr 2003;88(Suppl 1):7–16
   Google Scholar
• Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB. Posttraumatic stress disorder in the national comorbidity survey. Arch Gen Psychiatry 1995;52:1048–60
   Google Scholar
• DuPont RL, DuPont CM, Rice DP. Economic costs of anxiety disorders. In: Stein DJ, Hollander E, editors. Textbook of Anxiety Disorders. Washington, DC: American Psychiatric Publishing; 2002. pp.475–83
   Google Scholar
• Bruce SE, Vasile RG, Goisman RM, Salzman RM, Spencer M, Machan JT, et al. Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia. Am J Psychiatry 2003;160:1432–8
   PubMed Web of Science ®Google Scholar
• Xanax XR [package insert]. New York, NY: Pfizer, Inc; 2003
   Google Scholar
• Xanax [package insert]. New York, NY: Pfizer, Inc; 2003
   Google Scholar
• Nelson J, Chouinard G. Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Can J Clin Pharmacol 1999;6:69–83
   PubMedGoogle Scholar
• Ativan [package insert]. Philadelphia, Pa: Wyeth Laboratories Inc; 1999
   Google Scholar
• Serax [package insert]. Philadelphia, Pa: Wyeth Laboratories Inc; 2000
   Google Scholar
• Klonopin [package insert]. Nutley, NJ: Roche Laboratories Inc; 2001
   Google Scholar
• Ashton CH. Benzodiazepines: how they work and how to withdraw. Available from www.benzo.org.uk/manual [Last accessed 10 June 2004]
   Google Scholar
• Chlordiazepoxide [package insert]. Corona, Calif: Watson Laboratories Inc; 2001
   Google Scholar
• Frisium Tablets 10 mg. Electronic Medicines Compendium. Available from http://emc.medicines.org.uk/emc/assets/c/html/ displaydoc.asp?documentid=8298 [Last accessed 15 September 2004]
   Google Scholar
• Tranxene [package insert]. Deerfield, Ill: Ovation Pharmaceuticals, Inc; 2002
   Google Scholar
• Valium [package insert]. Nutley, NJ: Roche Laboratories Inc; 2000
   Google Scholar
• van Rooyen JM, Offermeier J. Pharmacokinetics of the benzodiazepines. S Afr Med J 1985;26(Suppl):10–3
   Google Scholar
• Klein E. The role of extended-release benzodiazepines in the treatment of anxiety: a risk-benefit evaluation with a focus on extended-release alprazolam. J Clin Psychiatry 2002;63(Suppl 14):27–33
   PubMed Web of Science ®Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296–310
   Google Scholar
• Pecknold J, Luth L, Munjack D, Alexander P. A double-blind, placebo-controlled, multicenter study with alprazolam and extended-release alprazolam in the treatment of panic disorder. J Clin Psychopharmacol 1994;14:314–21
   PubMed Web of Science ®Google Scholar
• Riss JR, Cloyd JC, Collins SD. The simulation of desmethyldiazepam (DMD) concentrations following missed daily doses of Tranxene-SD and Tranxene T-Tab. Poster presented at: 58th Annual Meeting of the American Epilepsy Society; December 3–8, 2004; New Orleans, La
   Google Scholar
• Gao P, Nixon PR, Skoug JW. Diffusion in HPMC gels. II. Prediction of drug release rates from hydrophilic matrix extended-release dosage forms. Pharmaceutical Res 1995;12:965–71
   Google Scholar
• Evans RL. Alprazolam-XR: a pharmacokinetic review. Psychiatric Ann 1993;23(Suppl):8–12
   Google Scholar
• Smith RB, Krobroth PD, Vanderlug JT, Phillips JP, Juhl RP. Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration. Psychopharmacology 1984;84:452–6
   Google Scholar
• Scavone M, Greenblatt DJ, Goddard JE, Friedman H, Harmatz JS, Shader RI. The pharmacokinetics and pharmacodynamics of sublingual and oral alprazolam in the post-prandial state. Eur J Clin Pharmacol 1992;42:439–43
   PubMed Web of Science ®Google Scholar
• Stahl S. Alprazolam-XR: dosage considerations. Psychiatric Ann 1993;23(Suppl):27–31
   Google Scholar
• Schweizer E. Once-daily control of panic disorder: evidence from a placebo-controlled study of alprazolam-XR. Psychiatric Ann 1993;23(Suppl):32–7
   Google Scholar
• DuPont RL. Anxiety and addiction: a clinical perspective on comorbidity. Bull Menninger Clinic 1995;59(Suppl A):A53–72
   Google Scholar
• Enkelmann R. Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology (Berl) 1991;105:428–32
   PubMed Web of Science ®Google Scholar
• Lydiard RB, Ballenger JC, Rickels K. A double-blind evaluation of the safety and efficacy of abecarnil, alprazolam, and placebo in outpatients with generalized anxiety disorder. Abecarnil Work Group. J Clin Psychiatry 1997;58(Suppl 11):11–8
   Google Scholar
• Moller HJ, Volz HP, Reimann IW, Stoll KD. Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. J Clin Psychopharmacol 2001;21:59–65
   PubMed Web of Science ®Google Scholar
• Elie R, Lamontagne Y. Alprazolam and diazepam in the treatment of generalized anxiety. J Clin Psychopharmacol 1984;4:125–9
   PubMed Web of Science ®Google Scholar
• Aden GC, O’Hair DE. Effectiveness of bedtime dosing of benzodiazepines: a placebo-controlled comparison of halazepam and clorazepate. Clin Ther 1980;3:209–18
   PubMed Web of Science ®Google Scholar
• Wallis TD, Valle-Jones JC, Craven JR, Hanks GW, Stonier PD. Single daily dose treatment of anxiety with clobazam or dipotassium clorazepate. Br J Clin Pharmacol 1979;7\(Suppl 1):123S–7
   Google Scholar
• Henderson JG. Value of a single night-time dose of potassium clorazepate in anxiety: a controlled trial comparison with diazepam. Scott Med J 1982;27:292–6
   PubMed Web of Science ®Google Scholar
• Ricca JJ. Clorazepate dipotassium in anxiety: a clinical trial with diazepam and placebo controls. J Clin Pharmacol 1972;12: 286–90
   Web of Science ®Google Scholar
• Burrows GD, Dumovic P, Smith JA, Norman T, Maguire K. A controlled comparative trial of clorazepate (Tranxene) and diazepam (Valium) for anxiety. Med J Aust 1977;2:525–8
   Google Scholar
• Magnus RV, Dean BC, Curry SH. Clorazepate: double blind crossover comparison of a single nightly dose with diazepam thrice daily in anxiety. Dis Nerv Syst 1977;38:819–21
   Google Scholar
• Magnus RV. Once-a-day potassium clorazepate in anxiety. Br J Clin Pract 1973;27:449–52
   PubMedGoogle Scholar
• Cooper AJ, Magnus RV, Rose M, Phanjoo A, Lancaster NP, Pollard P, et al. Controlled trial of dipotassium clorazepate (‘Tranxene’) in anxiety. Br J Psychiatry 1973;123:475–6
   PubMed Web of Science ®Google Scholar
• Wiersum J. Clorazepate dipotassium in anxiety: a double-blind trial with diazepam controls. Curr Ther Res Clin Exp 1972;14:442–8
   PubMed Web of Science ®Google Scholar
• Feltner DE, Crockatt JG, Dubovsky SJ, Cohn CK, Shrivastava RK, Targum SD, et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 2003;23:240–9
   PubMed Web of Science ®Google Scholar
• Ceulemans DL, Hoppenbrouwers ML, Gelders YG, Reyntjens AJ. The influence of ritanserin, a serotonin antagonist, in anxiety disorders: a double-blind placebo-controlled study versus lorazepam. Pharmacopsychiatry 1985;18:303–5
   PubMed Web of Science ®Google Scholar
• Pande AC, Crockatt JG, Feltner DE, Janney CA, Smith WT, Weisler R, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 2003;160:533–40
   PubMed Web of Science ®Google Scholar
• Spenard J, Caille G, de Montigny C, Vezina M, Ouellette J, Lariviere L, et al. Placebo-controlled comparative study of the anxiolytic activity and of the pharmacokinetics of oral and sublingual lorazepam in generalized anxiety. Biopharm Drug Dispos 1988;9:457–64
   PubMed Web of Science ®Google Scholar
• Laakmann G, Schule C, Lorkowski G, Baghai T, Kuhn K, Ehrentraut S. Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients. Psychopharmacology (Berl) 1998;136:357–66
   PubMed Web of Science ®Google Scholar
• Olajide D, Lader M. A comparison of buspirone, diazepam, and placebo in patients with chronic anxiety states. J Clin Psychopharmacol 1987;7:148–52
   PubMed Web of Science ®Google Scholar
• Pourmotabbed T, Mcleod DR, Hoehn-Saric R, Hipsley P, Greenblatt DJ. Treatment, discontinuation, and psychomotor effects of diazepam in women with generalized anxiety disorder. J Clin Psychopharmacol 1996;16:202–7
   Google Scholar
• Rickels K, Downing R, Schweizer E, Hassman H. Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 1993;50:884–95
   PubMed Web of Science ®Google Scholar
• Rickels K, Schweizer E, DeMartinis N, Mandos L, Mercer C. Gepirone and diazepam in generalized anxiety disorder: a placebo-controlled trial. J Clin Psychopharmacol 1997;17:272–7
   Google Scholar
• Rickels K, DeMartinis N, Aufdembrinke B. A double-blind, placebo-controlled trial of abecarnil and diazepam in the treatment of patients with generalized anxiety disorder. J Clin Psychopharmacol 2000;20:12–8
   Google Scholar
• Ansseau M, Papart P, Gerard MA, von Frenckell R, Franck G. Controlled comparison of buspirone and oxazepam in generalized anxiety. Neuropsychobiology 1990–1991;24: 74–8
   Google Scholar
• Strand M, Hetta J, Rosen A, Sorensen S, Malmstrom R, Fabian C, et al. A double-blind, controlled trial in primary care patients with generalized anxiety: a comparison between buspirone and oxazepam. J Clin Psychiatry 1990;51(Suppl):40–5
   Google Scholar
• Lemoine P, Rouillon F, Pouget D. Efficacy and withdrawal of clobazam, lorazepam and buspirone in the treatment of anxiety disorders [in French]. Encephale 1996;22:461–7
   Google Scholar
• Brogden RN, Heel RC, Speight TM, Avery GS. Clobazam: a review of its pharmacological properties and therapeutic use in anxiety. Drugs 1980;20:161–78
   PubMed Web of Science ®Google Scholar
• Donlon PT, Singer MM. Clobazam versus placebo for anxiety and tension in psychoneurotic outpatients. A multicenter collaborative study. J Clin Pharmacol 1979;19:297–302
   PubMed Web of Science ®Google Scholar
• Schjonsby HP, Gordon AE, Koeppen D. A three-month double-blind study of clobazam versus diazepam in out-patients suffering from neurotic disturbances. J Int Med Res 1979;7:404–10
   Google Scholar
• Rochiccioli P. Use of an anxiolytic agent: clobazam in children [in French]. Rev Int Pediatr 1977;59–62
   Google Scholar
• Disayavanish C, Mahatnirunkul S, Disayavanish P. Differential effects of three benzodiazepines in the treatment of neurotic patients. In: Hindmarch I, Stonier PD, Trimble M, editors. Clobazam: Human Psychopharmacology and Clinical Applications. London: The Royal Society of Medicine; 1985. pp.81–8
   Google Scholar
• Harrison C, Hindmarch I, Clyde CA. A comparison of clobazam and diazepam in anxious patients. In: Hindmarch I, Stonier PD, Trimble M, editors. Clobazam: Human Psychopharmacology and Clinical Applications. London: The Royal Society of Medicine; 1985. pp.89–100
   Google Scholar
• Thompson DJ. Comparison of drug treatment (clobazam) and relaxation therapy in the management of anxiety. Preliminary communication. In: Hindmarch I, Stonier PD, Trimble M, editors. Clobazam: Human Psychopharmacology and Clinical Applications. London: The Royal Society of Medicine; 1985. pp.101–3
   Google Scholar
• Allgulander C, Bandelow B, Hollander E, Montgomery SA, Nutt DJ, Pollack MH, et al. WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectr 2003;8(Suppl 1):53–61
   PubMed Web of Science ®Google Scholar
• DuPont RL, DuPont CM, DuPont Spencer E. Generalized anxiety disorder: a clinician’s guide to “the worry disease”. Dir Psychiatry 1999;XIX:133–45
   Google Scholar
• Hidalgo RB, Barnett SD, Davidson JR. Social anxiety disorder in review: two decades of progress. Int J Neuropsychopharmacol 2001;4:279–98
   Google Scholar
• Gelernter CS, Uhde TW, Cimbolic P, Arnkoff DB, Vittone BJ, Trancer ME, et al. Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study. Arch Gen Psychiatry 1991;48:938–45
   PubMed Web of Science ®Google Scholar
• Munjack DJ, Baltazar PL, Bohn PB, Cabe DD, Appleton AA. Clonazepam in the treatment of social phobia: a pilot study. J Clin Psychiatry 1990;51(Suppl):35–40
   Google Scholar
• Davidson JR, Potts N, Richichi E, Krishnan R, Ford SM, Smith R, et al. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 1993;13:423–8
   PubMed Web of Science ®Google Scholar
• Otto MW, Pollack MH, Gould RA, Worthington JJ 3rd, McArdle ET, Rosenbaum JF. A comparison of the efficacy of clonazepam and cognitive-behavioral group therapy for the treatment of social phobia. J Anxiety Disord 2000;14:345–58
   Google Scholar
• Davidson JR, Ford SM, Smith RD, Potts NL. Long-term treatment of social phobia with clonazepam. J Clin Psychiatry 1991;52(Suppl):16–20
   Google Scholar
• Connor KM, Davidson JR, Potts NL, Tupler LA, Miner CM, Malik ML, et al. Discontinuation of clonazepam in the treatment of social phobia. J Clin Psychopharmacol 1998;18:373–8
   PubMed Web of Science ®Google Scholar
• Sheehan DV. The management of panic disorder. J Clin Psychiatry 2002;63(Suppl 14):17–21
   PubMedGoogle Scholar
• Pollack MH, Simon NM, Worthington JJ, Doyle AL, Peters P, Toshkov F, et al. Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J Psychopharmacol 2003;17:276–82
   PubMed Web of Science ®Google Scholar
• Spiegel DA. Efficacy studies of alprazolam in panic disorder. Psychopharmacol Bull 1998;34:191–5
   PubMed Web of Science ®Google Scholar
• Andersch IC, Rosenberg NK, Kullingsjo H. Efficacy and safety of alprazolam, imipramine and placebo in the treatment of panic disorder. A Scandinavian multicentre study. Acta Psychiatr Scand 1991;365(Suppl 1):18–27
   Google Scholar
• Rickels K, Schweizer E, Weiss S, Zavodnick S. Maintenance drug treatment for panic disorder. II. Short- and long-term outcome after drug taper. Arch Gen Psychiatry 1993;50:61–8
   PubMed Web of Science ®Google Scholar
• Beauclair L, Fontaine R, Annable L, Holobow N, Chouinard G. Clonazepam in the treatment of panic disorder: a double-blind, placebo-controlled trial investigating the correlation between clonazepam concentrations in plasma and clinical response. J Clin Psychopharmacol 1994;14:111–8
   Google Scholar
• Valenca AM, Nardi AE, Nascimento I, Mezzasalma MA, Lopes FL, Zin W. Double-blind clonazepam vs placebo in panic disorder treatment. Arq Neuropsiquiatri 2000;58:1025–9
   PubMed Web of Science ®Google Scholar
• Valenca AM, Nardi AE, Mezzasalma MA, Nascimento I, Zin WA, Lopes FL, et al. Therapeutic response to benzodiazepine in panic disorder subtypes. Sao Paulo Med J 2003;121:77–80
   PubMedGoogle Scholar
• Rosenbaum JF, Moroz G, Bowden C. Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose-response study of efficacy, safety, and discontinuance. J Clin Psychopharmacol 1997;17:390–400
   Google Scholar
• Goddard AW, Brouette T, Almai A, Jetty P, Woods SW, Charney D. Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry 2001;58:681–6
   PubMed Web of Science ®Google Scholar
• Judd FK, Burrows GD, Marriott PF, Norman TR. A short term open clinical trial of clobazam in the treatment of patients with panic attacks. Int Clin Psychopharmacol 1989;4:285–9
   PubMed Web of Science ®Google Scholar
• Schweizer E, Rickels K. Buspirone in the treatment of panic disorder: a controlled pilot comparison with clorazepate [letter]. J Clin Pharmacol 1988;8:303
   Web of Science ®Google Scholar
• Dunner DL, Ishiki D, Avery DH, Wison LG, Hyde TS. Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: a controlled study. J Clin Psychiatry 1986;47:458–60
   Google Scholar
• Noyes RJ, Anderson DJ, Clancy J, Crowe RR, Slymen DJ, Ghoneim MM, et al. Diazepam and propranolol in panic disorder and agoraphobia. Arch Gen Psychiatry 1984;41:287–92
   PubMed Web of Science ®Google Scholar
• Noyes RJ, Burrows GD, Reich JH, Judd FK, Garvey MJ, Norman TR, et al. Diazepam versus alprazolam for the treatment of panic disorder. J Clin Psychiatry 1996;57:349–55
   PubMed Web of Science ®Google Scholar
• Charney DS, Woods SW. Benzodiazepine treatment of panic disorder: a comparison of alprazolam and lorazepam. J Clin Psychiatry 1989;50:418–23
   PubMed Web of Science ®Google Scholar
• de Jonghe F, Swinkels J, Tuynman-Qua H, Jonkers F. A comparative study of suriclone, lorazepam and placebo in anxiety disorder. Pharmacopsychiatry 1989;22:266–71
   Google Scholar
• Schweizer E, Pohl R, Balon R, Fox I, Rickels K, Yeragani VK. Lorazepam vs. alprazolam in the treatment of panic disorder. Pharmacopsychiatry 1990;23:90–3
   Google Scholar
• Braun P, Greenberg D, Dasberg H, Lerer B. Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. J Clin Psychiatry 1990;51:236–8
   PubMed Web of Science ®Google Scholar
• Davidson JR. Use of benzodiazepines in social anxiety disorder, generalized anxiety disorder, and posttraumatic stress disorder. J Clin Psychiatry 2004;65(Suppl 5):29–33
   PubMedGoogle Scholar
• Leonard HL, Topol D, Bukstein O, Hindmarsh D, Allen AJ, Swedo SE. Clonazepam as an augmenting agent in the treatment of childhood-onset obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 1994;33:792–4
   PubMed Web of Science ®Google Scholar
• Chouinard G. Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry 2004;65 (Suppl 5):7–12
   PubMed Web of Science ®Google Scholar
• Hewlett WA, Vinogradov S, Agras WS. Clomipramine, clonazepam, and clonidine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 1992;12:420–30
   Google Scholar
• Hollander E, Kaplan A, Stahl SM. A double-blind, placebo-controlled trial of clonazepam in obsessive-compulsive disorder. World J Biol Psychiatry 2003;4:30–4
   Google Scholar
• Wardle J. Behaviour therapy and benzodiazepines: allies or antagonists? Br J Psychiatry 1990;156:163–8
   PubMed Web of Science ®Google Scholar
• Lader MH. Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified? Eur Neuropsychopharmacol 1999;9(Suppl 6):S399–405
   PubMedGoogle Scholar
• Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996;153: 311–20
   Google Scholar
• Healey M, Pickens R, Meisch R, McKenna T. Effects of clorazepate, diazepam, lorazepam, and placebo on human memory. J Clin Psychiatry 1983;44:436–9
   PubMed Web of Science ®Google Scholar
• Scharf MB, Khosla N, Brocker N, Goff P. Differential amnestic properties of short- and long-acting benzodiazepines. J Clin Psychiatry 1984;45:51–3
   PubMed Web of Science ®Google Scholar
• Siegfried K, Koeppen D, Taeuber K, Badian M, Malerczyk V, Sittig W. A double-blind comparison of the acute effects of clobazam and lorazepam on memory and psychomotor functions. Royal Soc Med Int Symp Ser 1981;43:13–21
   Google Scholar
• Golombok S, Moodley P, Lader M. Cognitive impairment in long-term benzodiazepine users. Psychol Med 1988;18:365–74
   Google Scholar
• Buffett-Jerrott SE, Stewart SH. Cognitive and sedative effects of benzodiazepine use. Curr Pharm Des 2002;8:45–58
   Google Scholar
• Moore AR, O’Keeffe ST. Drug-induced cognitive impairment in the elderly. Drugs Aging 1999;15:15–28
   PubMed Web of Science ®Google Scholar
• Roehrs T, Roth T. Hypnotics: an update. Curr Neurol Neurosci Rep 2003;3:181–4
   PubMedGoogle Scholar
• Harris PG. Patient acceptance as a factor in the effectiveness of treatment: an open assessment of potassium clorazepate (‘Tranxene’) and lorazepam in anxiety. Curr Med Res Opin 1975;2:664–8
   Google Scholar
• DuPont RL, DuPont Spencer E, DuPont CM. Anxiety and insomnia. In: The Anxiety Cure. An Eight-Step Program for Getting Well. Hoboken, NJ: John Wiley & Sons; 2003. pp.200–6
   Google Scholar
• Souchet E, Lapeyre-Mestre M, Montastruc J-L. Drug related falls: a study in the French pharmacovigilance database. Pharmacoepidemiol Drug Saf 2005;14:11–6
   PubMed Web of Science ®Google Scholar
• Passaro A, Volpato S, Romagnoni F, Manzoli N, Zuliani G, Fellin R. Benzodiazepines with different half-life and falling in a hospitalized population: the GIFA study. J Clin Epidemiol 2000;53:1222–9
   PubMed Web of Science ®Google Scholar
• Herings RM, Stricker BH, de Boer A, Bakker A, Sturmans F. Benzodiazepines and the risk of falling leading to femur fractures: dosage more important than elimination half-life. Arch Intern Med 1995;155:1801–7
   Google Scholar
• Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, et al. Risk factors for hip fracture in white women. N Engl J Med 1995;332:767–73
   PubMed Web of Science ®Google Scholar
• Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA 1989;262:3303–7
   Google Scholar
• Ray WA, Griffin MR, Schaffner W, Baugh DK, Melton LJ 3rd. Psychotropic drug use and the risk of hip fractures. N Engl J Med 1987;31:363–9
   Google Scholar
• Rickels K, Schweizer E, Csanalosi I, Case WG, Chung H. Long-term treatment of anxiety and risk of withdrawal. Prospective comparison of clorazepate and buspirone. Arch Gen Psychiatry 1988;45:444–50
   Google Scholar
• Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. N Engl J Med 1993;328:1398–405
   PubMed Web of Science ®Google Scholar
• Moller HJ. Effectiveness and safety of benzodiazepines. J Clin Psychopharmacol 1999;19(6 Suppl 2):2S–11
   Google Scholar
• Kirkwood CK, Melton ST. Anxiety disorders. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy: A Pathophysiologic Approach. 5th edn. Chicago: McGraw-Hill; 2002. pp.1289–310
   Google Scholar
• Burrows GD, Norman TR, Judd FK, Marriott PF. Short-acting versus long-acting benzodiazepines: discontinuation effects in panic disorders. J Psychiatr Res 1990;24(Suppl 2):65–72
   PubMedGoogle Scholar
• Michelini S, Cassano GB, Frare F, Perugi G. Long-term use of benzodiazepines: tolerance, dependence and clinical problems in anxiety and mood disorders. Pharmacopsychiatry 1996; 29:127–34
   PubMed Web of Science ®Google Scholar
• Sussman N. Treating anxiety while minimizing abuse and dependence. J Clin Psychiatry 1993;54(Suppl):44–51
   Google Scholar
• Kan CC, Hilberink SR, Breteler MHM. Determination of the main risk factors for benzodiazepine dependence using a multivariate and multidimensional approach. Compr Psychiatry 2004;45:88–94
   Google Scholar
• Marriott S, Tyrer P. Benzodiazepine dependence. Avoidance and withdrawal. Drug Saf 1993;9:93–103
   PubMed Web of Science ®Google Scholar
• Martinez-Cano H, Vela-Bueno A, De Iceta M, Pomalima R, Martinez-Gras I, Sobrino M. Benzodiazepine types in high versus therapeutic dose dependence. Addiction 1996;91:1179–86
   PubMed Web of Science ®Google Scholar
• Longo LP, Johnson B. Addiction: Part I. Benzodiazepines – side effects, abuse risk and alternatives. Am Fam Physician 2000;61:2121–8
   Google Scholar
• Schweizer E, Rickels K. Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management. Acta Psychiatr Scand Suppl 1998;393:95–101
   PubMedGoogle Scholar
• DuPont RL, DuPont CM. Sedatives/hypnotics and benzodiazepines. In: Frances RJ, Miller SI, editors. Clinical Textbook of Addictive Disorders. New York: The Guilford Press; 1998. pp.120–49
   Google Scholar
• Owen RT, Tyrer P. Benzodiazepine dependence. A review of the evidence. Drugs 1983;25:385–98
   Google Scholar